Background
Methods
Study design and population
Sociodemographic variables
Definitions of chronic liver diseases
Assessment of quality of life
Data analyses
Results
Subjects’ baseline characteristics
Variables | HCV | NAFLD | Control |
P valuea
|
P valueb
|
P valuec
|
---|---|---|---|---|---|---|
(n = 346) | (n = 3333) | (n = 5982) | ||||
Age (years): mean (SE) | 48.86 (0.50) | 51.31 (0.36) | 47.50 (0.39) | 0.058 | <.0001 | <.0001 |
Body Mass Index (kg/m2): mean (SE) | 27.26 (0.41) | 33.66 (0.14) | 26.22 (0.10) | 0.037 | <.0001 | <.0001 |
Male | 228 (66.87 %) | 1817 (57.79 %) | 3103 (50.03 %) | <.0001 | <.0001 | 0.014 |
Race, | <.0001 | 0.034 | <.0001 | |||
White | 134 (63.53 %) | 1612 (72.46 %) | 3221 (75.15 %) | |||
Black | 137 (22.87 %) | 684 (10.88 %) | 1164 (9.50 %) | |||
Other | 75 (13.60 %) | 1037 (16.66 %) | 1597 (15.35 %) | |||
Comorbid disease, | ||||||
Diabetes | 56 (13.03 %) | 918 (20.75 %) | 503 (6.05 %) | <.0001 | <.0001 | 0.010 |
Hyperlipidemia | 177 (44.12 %) | 2051 (57.01 %) | 2286 (32.50 %) | <.0001 | <.0001 | <.0001 |
High blood pressure | 119 (29.46 %) | 2020 (58.99 %) | 2351 (38.35 %) | 0.009 | <.0001 | <.0001 |
Insulin resistance | 81 (47.34 %) | 2147 (66.03 %) | 442 (12.24 %) | <.0001 | <.0001 | <.0001 |
Heart disease | 47 (9.46 %) | 540 (13.83 %) | 558 (6.79 %) | 0.119 | <.0001 | 0.040 |
Asthma | 44 (14.62 %) | 394 (12.69 %) | 433 (7.87 %) | 0.001 | <.0001 | 0.468 |
NHANES cycle, | 0.135 | 0.696 | 0.152 | |||
2001–2002 | 71 (24.07 %) | 541 (16.24 %) | 1022 (16.73 %) | |||
2003–2004 | 49 (16.81 %) | 534 (17.15 %) | 856 (15.29 %) | |||
2005–2006 | 41 (13.80 %) | 499 (16.98 %) | 893 (16.47 %) | |||
2007–2008 | 75 (18.37 %) | 630 (17.07 %) | 1056 (16.63 %) | |||
2009–2010 | 53 (11.37 %) | 602 (15.22 %) | 1117 (16.74 %) | |||
2011–2012 | 57 (15.58 %) | 527 (17.35 %) | 1038 (18.13 %) |
Health related quality of life in NAFLD
Variables | HCV | NAFLD | Control |
P valuea
|
P valueb
|
P valuec
|
---|---|---|---|---|---|---|
(n = 346) | (n = 3333) | (n = 5982) | ||||
HRQOL-4 components, | ||||||
C1, | <.0001 | <.0001 | 0.005 | |||
Excellent | 20 (7.19 %) | 201 (6.49 %) | 863 (17.36 %) | |||
Very good/Good | 201 (60.75 %) | 2112 (71.02 %) | 4215 (72.22 %) | |||
Fair | 98 (24.81 %) | 831 (18.83 %) | 806 (9.09 %) | |||
Poor | 27 (7.24 %) | 189 (3.66 %) | 98 (1.32 %) | |||
C2 (no day = 0) | 187 (52.47 %) | 2000 (61.34 %) | 4048 (68.31 %) | <.0001 | <.0001 | 0.012 |
C3 (no day = 0) | 175 (46.58 %) | 2174 (64.07 %) | 3868 (62.60 %) | <.0001 | 0.257 | <.0001 |
C4 (no day = 0) | 230 (64.96 %) | 2663 (79.84 %) | 5050 (84.41 %) | <.0001 | <.0001 | <.0001 |
C1 | C2 | C3 | C4 | |
---|---|---|---|---|
Variable | OR a (95 % CI) | |||
Control | Reference | Reference | Reference | Reference |
HCV | 2.07 (1.48–2.88) | 1.82 (1.36–2.43) | 1.98 (1.52–2.58) | 2.83 (2.05–3.90) |
NAFLD | 1.22 (1.03–1.44) | 1.18 (1.03–2.08) | 0.95 (0.82–1.10) | 1.20 (1.02–1.41) |